Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MARJANI MAJID; BAGHAEI PARVANEH; KAZEMPOUR DIZAJI MEHDI; Gorji Bayani Pegah; FAHIMI FANAK; TABARSI PAYAM; VELAYATI ALI AKBAR

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Pharmaceutical Research Year:2016 | Volume:15 | Issue:1 Page(s): 247-252

Download Full-Text

View:

209

Download:

155

Cites:

Information Journal Paper

Title

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Author(s)

Keywords

Tuberculosis

Adverse effects

Silymarin

Drug induced hepatitis

Abstract

Hepatic toxicity is the most serious adverse effect of anti Tuberculosis drugs. This study was performed to evaluate the efficacy of Silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial, 70 new cases of pulmonary Tuberculosis were divided into two groups. The intervention group was assigned to receive Silymarin and the control group received placebo. Tuberculosis was treated by classic regimen consisting isoniazid, rifampin, pyrazinamide and ethambutol. No statistically significant difference was found between the two groups concerning the frequency of drug induced liver injury or mild elevation of liver enzymes. Silymarin was safe without any major side effect. Our results showed no significant hepatoprotective effect of Silymarin among patients on Tuberculosis treatment.

Cites

No record.

References

No record.

Cite

APA: Copy

MARJANI, MAJID, BAGHAEI, PARVANEH, KAZEMPOUR DIZAJI, MEHDI, Gorji Bayani, Pegah, FAHIMI, FANAK, TABARSI, PAYAM, & VELAYATI, ALI AKBAR. (2016). Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 15(1), 247-252. SID. https://sid.ir/paper/288534/en

Vancouver: Copy

MARJANI MAJID, BAGHAEI PARVANEH, KAZEMPOUR DIZAJI MEHDI, Gorji Bayani Pegah, FAHIMI FANAK, TABARSI PAYAM, VELAYATI ALI AKBAR. Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2016;15(1):247-252. Available from: https://sid.ir/paper/288534/en

IEEE: Copy

MAJID MARJANI, PARVANEH BAGHAEI, MEHDI KAZEMPOUR DIZAJI, Pegah Gorji Bayani, FANAK FAHIMI, PAYAM TABARSI, and ALI AKBAR VELAYATI, “Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 15, no. 1, pp. 247–252, 2016, [Online]. Available: https://sid.ir/paper/288534/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops